ICU · SeaStar Medical Holding Corp · Investor Relations
Substantial doubt about the company's ability to continue as a going concern.
“The Company believes that these conditions raise substantial doubt about its ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-10-05 |
SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds
DENVER, Oct. 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, today announced the entry into |
| 2026-10-02 |
SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026
DENVER, Oct. 02, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that a late-breaking abstract |
| 2026-10-01 |
New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical’s SCD Therapy for Acute Kidney Injury (AKI)
New codes streamline hospital billing, enable tracking of clinical outcomes, and expand access to QUELIMMUNE ® (SCD-PED) therapy Universal codes establish a framework to enable billing for future potential SCD indications that require renal replacement therapy DENVER, Oct. |
| 2026-09-29 |
SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026
Dr. Chung to deliver an oral presentation highlighting QUELIMMUNE ®, an advanced extracorporeal therapy for critically ill pediatric patients with acute kidney injury (AKI) DENVER, Sept. 29, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare |
| 2026-09-24 |
SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy
Prestigious honor recognizes Dr. Humes’ pioneering work in developing the Selective Cytopheretic Device (SCD) therapy, commercialized by SeaStar Medical as QUELIMMUNE ® for critically ill pediatric patients with acute kidney injury (AKI) SeaStar Medical’s SCD development pipeline of indications |
| 2026-09-10 |
SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference
DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, Chief Executive |
| 2026-08-12 |
SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates
Added 3 top-rated children’s hospitals to QUELIMMUNE ® pediatric acute kidney injury (AKI) customer base, increasing net revenue 82% versus second quarter 2025 Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI Obtained ICD-10-PCS codes to enable |
| 2026-08-06 |
SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026
DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its second |
| 2026-07-14 |
SeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI)
Sponsors educational summit of leading pediatric AKI health care experts Announces best practices webinar to further advance new treatment options DENVER, July 14, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on |
| 2026-06-23 |
SeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney Injury
Enables standardized inpatient hospital billing for QUELIMMUNE ® (SCD-PED) therapy Universal code paves the way for billing of future potential SCD therapies requiring renal replacement therapy DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a |
| 2026-06-22 |
SeaStar Medical to Present at Upcoming Investor Summit Conference
DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive |
| 2026-05-13 |
SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates
Added 7 top-rated children’s hospitals to QUELIMMUNE ® pediatric acute kidney injury (AKI) customer base, increasing first quarter revenue 69% versus first quarter 2025 revenue Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI Initiated efforts for the |
| 2026-05-06 |
SeaStar Medical to Report First Quarter Financial Results on May 13, 2026
DENVER, May 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter |
| 2026-03-30 |
SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026
Results from pediatric patients in the SAVE Registry shows no device-related adverse events or immunosuppression and continued strong survival data In vitro analysis of the SeaStar Medical SCD indicates modulation of the immune response, shifting monocytes towards an anti-inflammatory, reparative |
| 2026-03-25 |
SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Added top-rated children’s hospitals to QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer base Completed enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry Exceeded 50% enrollment milestone in pivotal trial of SCD therapy in adult patients with AKI Advanced pipeline |